Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 13:e252723.
doi: 10.1001/jamadermatol.2025.2723. Online ahead of print.

Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa

Louise Gouvrion  1 , Maia Delage  2 , Axel P Villani  3 , Sarah Le Naour  4 , Charlotte Fite  5 , Charles Cassius  6 , Laurent Misery  7 , Bénédicte Oulès  8 , Alice Fayad  9 , Aurore Brun  10 , Christelle Pruvost-Balland  11 , Gilles Safa  12 , Mathilde Tardieu  13 , Sébastien Buche  14 , Annabel Maruani  15 , Gaëlle Quéreux  4 , Aude Nassif  2 , Agathe Guenego  16 , Ronan Thibault  16   17 , Alain Dupuy  1   18 , Florence Poizeau  1   18 ; IGDO (Institut de Dermatologie du Grand-Ouest); HS-France group of the French Society of Dermatology
Affiliations

Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa

Louise Gouvrion et al. JAMA Dermatol. .
No abstract available

Plain language summary

This cohort study investigates the potential therapeutic benefits of glucagon-like peptide-1 receptor agonists in patients with hidradenitis suppurativa.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Delage reported personal fees from Novartis and UCB outside the submitted work. Prof Villani reported personal fees from AbbVie, Almirall, Amgen, Bristol Myers Squibb, Lilly, Janssen, LEO Pharma, MSD, Novartis, and UCB during the conduct of the study. Prof Misery reported personal fees from AbbVie, Novartis, and UCB outside the submitted work. Dr Oulès reported conference invitations from Novartis and UCB outside the submitted work. Dr Fayad reported nonfinancial support from AbbVie and Novartis, as well as personal fees from UCB and LEO Pharma outside the submitted work. Dr Pruvost-Balland reported personal fees from Novartis and UCB outside the submitted work. Prof Thibault reported nonfinancial support from Novo Nordisk and Lilly outside the submitted work. Prof Dupuy reported personal fees from Sanofi, MSD, Amgen, and Kyowa Kirin, as well as nonfinancial support from AbbVie, Janssen-Cilag, Almirall, Pierre Fabre, and UCB, outside the submitted work. Dr Poizeau reported personal fees from Bristol Myers Squibb, Novartis, LEO Pharma, UCB, and Janssen outside the submitted work. No other disclosures were reported.

References

    1. Krajewski PK, Matusiak Ł, Szepietowski JC. Adipokines as an important link between hidradenitis suppurativa and obesity: a narrative review. Br J Dermatol. 2023;188(3):320-327. doi: 10.1093/bjd/ljac107 - DOI - PubMed
    1. Weber I, Giefer J, Martin KL. Effects of exercise and dietary modifications on hidradenitis suppurativa: a systematic review. Am J Clin Dermatol. 2023;24(3):343-357. doi: 10.1007/s40257-023-00756-w - DOI - PubMed
    1. Posada Posada MI, Alora MB, Lima XTV. Impact of semaglutide use in obese and diabetic patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. Published online October 19, 2024. doi: 10.1111/jdv.20392 - DOI - PubMed
    1. Nicolau J, Nadal A, Sanchís P, Pujol A, Masmiquel L, Nadal C. Liraglutide for the treatment of obesity among patients with hidradenitis suppurativa. Med Clin (Barc). 2024;162(3):118-122. doi: 10.1016/j.medcli.2023.11.007 - DOI - PubMed
    1. Lyons D, Louly Nathan A, Pender E, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191(4):631-633. doi: 10.1093/bjd/ljae216 - DOI - PubMed

LinkOut - more resources